When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Background In patients undergoing allogeneic hematopoietic stem-cell transplantation
(HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against …

PURPOSE Calcineurin inhibitors (CNI) are standard components of graft-versus-host
disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT). Prior data …

The diverse immunomodulatory properties of mesenchymal stem/stromal cells (MSCs) may
be exploited for treatment of a multitude of inflammatory conditions. MSCs have long been …

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor
transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft …

Background Prevention of graft-versus-host disease (GvHD) without malignant relapse is the
overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate …

Chronic graft versus host disease (GVHD) is a major cause of morbidity and mortality after
allogeneic hematopoietic cell transplantation. Clinically, chronic GVHD is a pleiotropic …

Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …